Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Aug 14, 2023

BUY
$79.22 - $105.37 $253,979 - $337,816
3,206 Added 13.23%
27,437 $2.8 Million
Q1 2023

May 15, 2023

SELL
$30.85 - $93.17 $83,788 - $253,049
-2,716 Reduced 10.08%
24,231 $2.2 Million
Q4 2022

Feb 14, 2023

SELL
$22.15 - $42.11 $698,876 - $1.33 Million
-31,552 Reduced 53.94%
26,947 $1.02 Million
Q3 2022

Nov 14, 2022

BUY
$19.41 - $36.49 $606,504 - $1.14 Million
31,247 Added 114.66%
58,499 $1.47 Million
Q2 2022

Aug 15, 2022

SELL
$20.71 - $36.5 $177,029 - $312,002
-8,548 Reduced 23.88%
27,252 $828,000
Q3 2021

Nov 12, 2021

BUY
$100.0 - $143.02 $110,000 - $157,322
1,100 Added 3.17%
35,800 $3.6 Million
Q2 2021

Aug 12, 2021

BUY
$78.27 - $151.29 $2.45 Million - $4.74 Million
31,339 Added 932.43%
34,700 $4.91 Million
Q1 2021

May 17, 2021

BUY
$94.25 - $132.81 $25,541 - $35,991
271 Added 8.77%
3,361 $335,000
Q4 2020

Feb 03, 2021

SELL
$102.03 - $184.62 $13,263 - $24,000
-130 Reduced 4.04%
3,090 $382,000
Q3 2020

Nov 16, 2020

SELL
$93.53 - $163.34 $27,123 - $47,368
-290 Reduced 8.26%
3,220 $314,000
Q2 2020

Aug 12, 2020

SELL
$126.3 - $176.56 $3.98 Million - $5.56 Million
-31,490 Reduced 89.97%
3,510 $548,000
Q1 2020

May 06, 2020

BUY
$124.16 - $247.74 $608,384 - $1.21 Million
4,900 Added 16.28%
35,000 $5.05 Million
Q3 2019

Nov 12, 2019

BUY
$71.26 - $95.75 $192,402 - $258,525
2,700 Added 9.85%
30,100 $2.42 Million
Q2 2019

Aug 14, 2019

BUY
$77.72 - $94.35 $217,616 - $264,180
2,800 Added 11.38%
27,400 $2.59 Million
Q1 2019

May 13, 2019

BUY
$51.9 - $101.79 $290,640 - $570,024
5,600 Added 29.47%
24,600 $2.1 Million
Q4 2018

Feb 11, 2019

BUY
$48.76 - $76.44 $136,528 - $214,032
2,800 Added 17.28%
19,000 $1.07 Million
Q2 2018

Aug 03, 2018

BUY
$19.94 - $40.96 $323,028 - $663,552
16,200 New
16,200 $567,000

Others Institutions Holding RETA

About REATA PHARMACEUTICALS INC


  • Ticker RETA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 31,583,200
  • Description
  • Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases. The company is developing Phase 3 clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney diseas...
More about RETA
Track This Portfolio

Track State Of Wisconsin Investment Board Portfolio

Follow State Of Wisconsin Investment Board and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of State Of Wisconsin Investment Board, based on Form 13F filings with the SEC.

News

Stay updated on State Of Wisconsin Investment Board with notifications on news.